therapeutics

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
James Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2020-219406; DOI: 10.1136/annrheumdis-2020-219406
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H Pillinger

Annals of the Rheumatic Diseases May 2021, 80 (5) 550-557; DOI: 10.1136/annrheumdis-2020-219174
Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al
Alexis Mathian, Zahir Amoura

Annals of the Rheumatic Diseases May 2021, 80 (5) e72; DOI: 10.1136/annrheumdis-2020-218146
Correspondence on ‘Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab’
Francesco Messina, Francesca Pampaloni, Stefano Piaserico

Annals of the Rheumatic Diseases May 2021, 80 (5) e79; DOI: 10.1136/annrheumdis-2020-218029
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Yoshino Inoue, Yoshihisa Fujino, Yoshiya Tanaka

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2020-219699; DOI: 10.1136/annrheumdis-2020-219699
Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by de Wolff et al
Renaud Felten, Jacques-Eric Gottenberg

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2021-220220; DOI: 10.1136/annrheumdis-2021-220220
Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial
Ho So, Isaac T Cheng, Sze-Lok Lau, Evelyn Chow, Tommy Lam, Vivian W Hung, Edmund K Li, James F Griffith, Vivian W Lee, Lin Shi, Junbin Huang, Kitty Yan Kwok, Cheuk-Wan Yim, Tena K Li, Vincent Lo, Jolie Lee, Jack Jock-Wai Lee, Ling Qin, Lai-Shan Tam

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2021-219846; DOI: 10.1136/annrheumdis-2021-219846
Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial’
Liseth de Wolff, Suzanne Arends, Gwenny M Verstappen, Arjan Vissink, Frans G M Kroese, Hendrika Bootsma

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220198; DOI: 10.1136/annrheumdis-2021-220198
Response to: ‘Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey’ by Plüß et al
Alexis Mathian, Zahir Amoura

Annals of the Rheumatic Diseases Apr 2021, 80 (4) e53; DOI: 10.1136/annrheumdis-2020-218069
Response to: ‘Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak’ by Holubar et al
Alexis Mathian, Zahir Amoura

Annals of the Rheumatic Diseases Apr 2021, 80 (4) e57; DOI: 10.1136/annrheumdis-2020-217988

Main menu

therapeutics

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

therapeutics

Pages